Expanding the Patient Pool for Rilonacept

Recurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed rilonacept, an interleukin-1 cytokine trap, to be an effective therapeutic option for patients with pericarditis recurrence. This case series demonstrates the utility and challenges of rilonacept use in the types of patients excluded from RHAPSODY.